Abstract Background Treatment-resistant schizophrenia (TRS), affecting roughly one-third of patients, shows poor response to standard antipsychotics and may reflect more severe or distinct neurophysiological disruptions compared to treatment-responsive cases. Prior evidence from imaging and other methods suggested cort...
A. Barone, G. Senerchia, G. De Simone et al.· International Journal of Neu...· 0 citations
Abstract Background About a third of schizophrenia patients are refractory to antipsychotics, a condition characterized by poor clinical and functional outcomes known as treatment-resistant schizophrenia (TRS). The disorganization domain may represent the leading factor in categorizing a schizophrenia patient as affect...
M. Ciccarelli, F. Iasevoli, A. Barone et al.· International Journal of Neu...· 0 citations
Abstract Background Treatment-resistant schizophrenia (TRS), defined as the persistence of symptoms despite adequate antipsychotic treatment, remains frequently underrecognized, with clozapine, the gold standard, introduced only after an average delay of 4–9 years. In this study, we aimed to identify which Positive and...
L. Vellucci, P. Mirra, A. Nasti et al.· International Journal of Neu...· 0 citations
BACKGROUND
The Fusiform Gyrus (FG), a brain region relevant for the interaction between cognitive processes and emotional behavior, especially emotion recognition and interpretation of social cues, has been linked to the pathophysiology of schizophrenia conceptualized as a disorder of aberrant synaptic function and bra...
M. Ciccarelli, B. Mazza, A. Nasti et al.· Neuroscience and Biobehavior...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
